Proteostasis Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2007-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.proteostasis.com
Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- Proteostasis Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03591094
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- Proteostasis Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03500263
- Locations
- 🇬🇧
Western General Hospital, Edinburgh, United Kingdom
🇬🇧Queen Elizabeth University Hospital, Glasgow, United Kingdom
🇬🇧Medicines Evaluation Unit, Manchester, United Kingdom
Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Proteostasis Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03258424
- Locations
- 🇬🇧
Celerion, Belfast, United Kingdom
🇬🇧Medicines Evaluation Unit, Manchester, United Kingdom
Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis
- Conditions
- Cystic Fibrosis - CompleteHealthy Volunteer - Complete
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Proteostasis Therapeutics, Inc.
- Target Recruit Count
- 179
- Registration Number
- NCT03251092
- Locations
- 🇺🇸
Banner University of Arizona Medical Center, Tucson, Arizona, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis
- Conditions
- Healthy VolunteerCystic Fibrosis
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Proteostasis Therapeutics, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT03140527
- Locations
- 🇺🇸
Maine Medical Center, Portland, Maine, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2018-05-24
- Lead Sponsor
- Proteostasis Therapeutics, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT02846142
Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Proteostasis Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT02718495
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
🇺🇸Northwestern University Memorial Hospital, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States